Market Overview

Editas Get A Vetr Upgrade To Strong Buy

Related EDIT
Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss
Jim Cramer Shares His Thoughts On Goodyear, Applied Materials And More
Trump set to sign "right to try" bill; biotechs rally (Seeking Alpha)

The Vetr crowd Monday upgraded their rating for Editas Medicine Inc (NASDAQ: EDIT), from 4 stars (Buy), issued 313 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Editas has traded fairly sporadically over the course of March, which began with the stock entering a trough of over 18 percent to a low of $20.40.

The stock rallied back above $26 with a mid-month announcement the company was entering an R&D partnership with Allergan plc Ordinary Shares (NYSE: AGN), but fell back below $22.50 shortly after when it reported an offering of 4 million shares of common stock valued at $22.50.

Learn how crowdsourced ratings could help you time the market.

Curretnly, the vetr crowd's average target price for Editas is up at $27.14, which is still below the average analyst target price of $33.50. Less than 2 percent of Vetr users are holding EDIT in their watch lists.

Latest Ratings for EDIT

Mar 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Mar 2018BarclaysMaintainsOverweightOverweight
Jan 2018SunTrust Robinson HumphreyUpgradesHoldBuy

View More Analyst Ratings for EDIT
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Price Target Crowdsourcing Analyst Ratings


Related Articles (AGN + EDIT)

View Comments and Join the Discussion!